Cefuroxime PO for Bacteremic UTI

The available pharmacokinetic-pharmacodynamic data supports cefuroxime as a PO 💊 step-down option in patients with complicated urinary tract infections with secondary bacteremia🩸. True or False?

How did others respond?

Reveal the answer

Best Answer

False

Explanation: At a dose of 500 mg BID, good pharmacokinetic-pharmacodynamic target attainment may be only achieved up to an MIC of 0.5 mg/L which is below the susceptible breakpoint. Confirmation of an acceptable MIC may not be possible with standard automated susceptibility testing. MICs within an acceptable range are so rare that USCAST does not support the use of cefuroxime in systemic infections due to Enterbacterales.

Click here for details/references

Copyright © 2026 KASIC Inspiro Theme by WPZOOM